Developed by Covishield AstraZeneca and produced by covishield Developed and manufactured by AstraZeneca. Serum Institute of India.It was one of the widely administered COVID vaccines in India.
What did AstraZeneca say about the side effects of the vaccine?
Right now, AstraZeneca It is facing a class action lawsuit in the UK over allegations that its vaccine caused deaths. 51 lawsuits were filed against him
In one of the court documents, AstraZeneca He admitted that Covishield “can cause TTS in very rare cases.” In one of the court documents, AstraZeneca admitted: covishield “in very rare cases it may cause TTS”. In one of the court documents, AstraZeneca admitted that Covishield “may cause TTS“. TTS It means Thrombosis with Thrombocytopenia Syndrome.
What is TTS?
Thrombosis with thrombocytopenia syndrome (TTS) is a rare but serious condition characterized by blood clot formation (thrombosis) combined with a low platelet count (thrombocytopenia).
TTS It typically presents with symptoms such as severe headaches, abdominal pain, swelling in the legs, shortness of breath and neurological disorders. Diagnosis includes blood tests to evaluate platelet levels and imaging studies to detect blood clots.
Treatment for TTS involves a multidisciplinary approach that includes hospitalization, anticoagulation therapy to prevent further clotting, and supportive care. intravenous immunoglobulin (IVIG) and plasma exchange may also be used to stabilize platelet levels and manage immune-mediated reactions.Treatment for TTS involves a multidisciplinary approach that includes hospitalization, anticoagulation therapy to prevent further clotting, and supportive care. Intravenous immunoglobulin (IVIG) and plasma exchange may also be used to stabilize platelet levels and manage immune-mediated reactions.Treatment TTS It involves a multidisciplinary approach that includes hospitalization, anticoagulation therapy to prevent further clotting, and supportive care. Intravenous immunoglobulin (IVIG) and plasma exchange may also be used to stabilize platelet levels and manage immune-mediated reactions.
Healthcare providers monitor patients closely TTS due to the potential for serious complications, including organ damage and death. Prompt diagnosis and management are essential to improve outcomes in individuals affected by this rare but critical syndrome.
“TTS It is basically thrombosis with thrombocytopenia syndrome, which occurs with clots and low platelet counts in blood vessels in the brain or elsewhere. In very rare cases it has been known to be caused by certain types of vaccines and also by other causes. Medical expert Dr Rajeev Jayadevan told ANI that according to the World Health Organisation, adenovirus vector vaccines in particular have been rarely associated with this condition. “Although COVID vaccines have prevented a large number of deaths, reports of these extremely rare but potentially serious immune-mediated events have also been reported in reputed journals,” Dr Jayadevan added.“TTS is basically thrombosis with thrombocytopenia syndrome, which is accompanied by the formation of clots in blood vessels in the brain or elsewhere and a low platelet count. In very rare cases, it is known to occur following certain types of vaccinations and also from other causes. WHO“Adenovirus vector vaccines, in particular, are rarely associated with this condition,” medical expert Dr Rajeev Jayadevan told ANI. “Although COVID vaccines have prevented a large number of deaths, reports of these extremely rare but potentially serious immune-mediated events have also been published in reputable journals,” Dr Jayadevan added.
Expert explains what causes head and neck cancers
In its report in 2023, the World Health Organization (WHO) said that TTS emerged as a new adverse event after vaccination in individuals vaccinated with COVID-19 non-replicative adenovirus vector-based vaccines. This refers to the AstraZeneca COVID-19 ChAdOx-1 vaccine and the Johnson & Johnson (J&J) Janssen COVID-19 vaccine. Ad26.COV2-S vaccines.In its report in 2023, the World Health Organization (WHO) said that TTS emerged as a new adverse event after vaccination in individuals vaccinated with COVID-19 non-replicative adenovirus vector-based vaccines. This refers to: AstraZeneca COVID-19 ChAdOx-1 vaccine and Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccines.In its report in 2023, the World Health Organization (WHO) said that TTS emerged as a new adverse event after vaccination in individuals vaccinated with COVID-19 non-replicative adenovirus vector-based vaccines. This refers to AstraZeneca COVID-19 ChAdOx-1 vaccine and Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccines.The World Health Organization (WHO) stated in its 2023 report that TTS emerged as a new adverse event after vaccination in vaccinated individuals. COVID-19 non-replicative adenovirus vector-based vaccines. This refers to AstraZeneca In its report in 2023, the World Health Organization (WHO) said that TTS emerged as a new adverse event after vaccination in individuals vaccinated with COVID-19 non-replicative adenovirus vector-based vaccines. This refers to the AstraZeneca COVID-19 ChAdOx-1 vaccine and the Johnson & Johnson (J&J) vaccine. janssen COVID-19 Ad26.COV2-S vaccines.The World Health Organization (WHO) said the following in its 2023 report: TTS Covid-19 non-replicating adenovirus emerged as a new adverse event following vaccination in individuals vaccinated with vector-based vaccines. This refers to the AstraZeneca COVID-19 ChAdOx-1 vaccine and the Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccines.In 2023, the World Health Organization (WHO) said in its report that TTS has emerged as a new adverse event following vaccination in individuals vaccinated with COVID-19 non-replicating adenovirus vector-based vaccines. This refers to the AstraZeneca COVID-19 ChAdOx-1 vaccine and the Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccines.In 2023, World Health Organization (WHO) said in its report that TTS emerged as a new adverse event after vaccination in individuals vaccinated with COVID-19 non-replicating adenovirus vector-based vaccines. This refers to the AstraZeneca COVID-19 ChAdOx-1 vaccine and the Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccines.
“TTS is a serious and life-threatening adverse event. WHO has issued this interim emergency guidance to raise awareness of TTS in the following context: COVID-19 “Assist healthcare providers in the evaluation and management of vaccination and potential TTS cases,” WHO’s 2023 statement states.“TTS It is a serious and life-threatening adverse event. WHO has published this interim emergency guidance to raise awareness of: “TTS is a serious and life-threatening adverse event. WHO “We have issued this interim emergency guidance to increase awareness of TTS in the context of COVID-19 vaccination and to assist healthcare providers in the evaluation and management of potential TTS cases.”
AstraZeneca reaffirms vaccine safety amid rare side effect concerns
“We offer our condolences to everyone who has lost loved ones or reported health problems. Patient safety is our top priority and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines. AstraZeneca the spokesman said amid concerns of side effects. This follows a recent confession. A spokesperson for AstraZeneca said: “We offer our condolences to everyone who has lost a loved one or reported a health issue. Patient safety is our top priority and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines.” This comes after pharmaceutical company AstraZeneca recently admitted it has a Covid vaccine. covishield and Vaxzevria “may cause Thrombosis Thrombocytopenia Syndrome (TTS) in very rare cases.”A spokesperson for AstraZeneca said: “We offer our condolences to everyone who has lost a loved one or reported a health issue. Patient safety is our top priority and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines.” This comes after pharmaceutical company AstraZeneca admitted that its Covid vaccines, Covishield and Vaxzevria, “may cause Thrombosis Thrombocytopenia Syndrome in very rare cases” (TTS).”
(With inputs from ANI)
